ASTELLAS PHARMA

PD-1 inhibition with pembrolizumab before and after surgery significantly improves 5-year overall survival (86.6% vs 81.7%) in high-risk early triple-negative breast cancer, according to KEYNOTE-522 trial results.

Desai Sethi Urology Institute researchers found that prostate cancer patients with the adrenal-permissive HSD3B1 allele had better survival outcomes when treated with ADT plus enzalutamide or ADT plus nonsteroidal antiandrogen, reversing poor genetic outcomes.

DelveInsight's 'Gene Therapy Competitive Landscape 2024' report covers 250+ companies and 300+ therapies, highlighting key players like Candel Therapeutics, SillaJen Biotherapeutics, and Wuhan Binhui Biotechnology. The report assesses gene therapy products by type, stage, route of administration, and molecule type, and includes inactive pipeline products. Notable therapies in development include ABECMA, ADSTILADRIN, and BREYANZI. Recent clinical trials include Sangamo Therapeutics' ST-920 for Fabry disease and Regenxbio's RGX-202 for Duchenne.

DelveInsight's 'Spinal Muscular Atrophy Pipeline Insight, 2024' report details 18+ companies developing 20+ therapies, including key players like Scholar Rock, Biogen, and Roche. The report covers clinical trials, MOA, ROA, recent developments, and emerging therapies like ACTX-401, Apitegromab, and GYM329, expected to impact the SMA market.

The U.S. Translational Regenerative Medicine Market is projected to grow from USD xx.x Billion in 2023 to USD xx.x Billion by 2031, with a CAGR of xx.x%. Key applications include orthopedics, cardiovascular, oncology, wound healing, and others. Major manufacturers include Athersys, Avita Medical, AxoGen, and more. The market's future is promising yet complex, with regional variations and emerging trends.

FDA warns of rare, serious liver injuries from fezolinetant (Veozah), updating prescribing info to include monthly liver blood tests for 2 months after initiation, then at months 3, 6, and 9, and advising immediate discontinuation at signs of liver injury.

Immunotherapy less risky for non-small cell lung cancer patients with BMI under 28, while chemotherapy is optimal for those with BMI 28 or higher, according to Osaka Metropolitan University study.

Vir Biotechnology appoints Jason O’Byrne as CFO, effective October 2, 2024. O’Byrne brings over 20 years of finance and operations experience, previously serving as CFO at Caribou Biosciences and Senior VP of Finance at Audentes Therapeutics.

Vir Biotechnology Inc. appoints Jason O'Byrne as EVP and CFO, effective October 2, 2024. O'Byrne brings over two decades of financial and operational experience, including roles at Caribou Biosciences and Audentes Therapeutics. Vir focuses on infectious diseases and cancer treatments, with recent FDA approvals and a licensing deal with Sanofi. The company is restructuring, reducing workforce by 25%, and faces financial challenges despite holding more cash than debt.

Vir Biotechnology appoints Jason O'Byrne as EVP and CFO, effective October 2, 2024. O'Byrne, with over 20 years of finance and operations experience, joins from Caribou Biosciences, where he led finance and operations. He previously served as SVP of Finance at Audentes Therapeutics and held roles at Genentech. O'Byrne holds a Bachelor of Applied Science in Mechanical Engineering and an MBA in Finance.